Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

15-09-2022 | Mastectomy | Breast Oncology

Points to Consider Regarding De-Escalation Surgery in High-Risk Breast Cancer

Authors: Giovanni Corso, MD, PhD, Francesca Magnoni, MD, PhD, Paolo Veronesi, MD

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Abstract

For women affected by breast cancer who carry germline BRCA1/2 pathogenic variants, the classic standard treatment consists of therapeutic unilateral mastectomy and risk-reducing contralateral mastectomy. However, data from recent literature demonstrate that for women treated with breast-conserving surgery who receive adequate adjuvant treatments, the increased risk of locoregional recurrences and a breast cancer-related prognosis is not significant. This review describes the clinical factors that could help clinicians decide either against or in favor of a more aggressive type of breast cancer surgery.
Literature
1.
2.
Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144:443–55.CrossRefPubMed
3.
Nelson JA, Rubenstein RN, Haglich K, et al. Analysis of a trend reversal in US lumpectomy rates from 2005 through 2017 using 3 nationwide data sets. JAMA Surg. 2022;157:702–11.CrossRefPubMed
4.
Morrow M. Surgery and prophylactic surgery in hereditary breast cancer. Breast. 2022;62(Suppl 1):S63–6.CrossRefPubMed
5.
Corso G, Magnoni F. Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations. Eur J Cancer Prev. 2021;30:311–4.CrossRefPubMed
6.
Burstein HJ, Curigliano G, Loibl S, et al. Members of the St.Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St.Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541–57.CrossRefPubMed
7.
Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, et al. Breast cancer risk genes: association analysis in more than 113,000 women. N Engl J Med. 2021;384:428–39.CrossRef
8.
Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887–92.CrossRefPubMed
9.
Poehls UG, Hack CC, Wunderle M, et al. Awareness of breast cancer incidence and risk factors among healthy women in Germany: an update after 10 years. Eur J Cancer Prev. 2019;28:515–21.CrossRefPubMed
10.
Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017;165:193–200.CrossRefPubMedPubMedCentral
11.
Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358:1389–99.CrossRef
12.
Corso G, Feroce I, Intra M, et al. BRCA1/2 germline missense mutations: a systematic review. Eur J Cancer Prev. 2018;27:279–86.CrossRefPubMed
13.
Shimelis H, Mesman RLS, Von Nicolai C, et al. BRCA2 Hypomorphic missense variants confer moderate risks of breast cancer. Cancer Res. 2017;77:2789–99.CrossRefPubMedPubMedCentral
14.
Li H, Engel C, de la Hoya M, et al. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genet Med. 2022;24:119–29.CrossRefPubMed
15.
Girardi A, Magnoni F, Vicini E, et al. CDH1 germline mutations in families with hereditary lobular breast cancer. Eur J Cancer Prev. 2022;31:274–8.CrossRefPubMed
16.
Yadav S, Hu C, Nathanson KL, et al. Germline pathogenic variants in cancer predisposition genes among women with invasive lobular carcinoma of the breast. J Clin Oncol. 2021;39:3918–26.CrossRefPubMed
17.
18.
Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.CrossRefPubMed
19.
Campbell I, Scott N, Seneviratne S, et al. Breast cancer characteristics and survival differences between Maori, Pacific, and other New Zealand women included in the Quality Audit Program of Breast Surgeons of Australia and New Zealand. Asian Pac J Cancer Prev. 2015;16:2465–72.CrossRefPubMed
20.
Corso G, Corso F, Bellerba F, et al. Geographical distribution of E-cadherin germline mutations in the context of diffuse gastric cancer: a systematic review. Cancers Basel. 2021;13:1269.CrossRefPubMedPubMedCentral
21.
Keinan-Boker L, Baron-Epel O, Fishler Y, et al. Breast cancer trends in Israeli Jewish and Arab women, 1996–2007. Eur J Cancer Prev. 2013;22:112–20.CrossRefPubMed
22.
Offit K, Gilewski T, McGuire P, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996;347:1643–5.CrossRefPubMed
23.
Robson M, Dabney MK, Rosenthal G, et al. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test. 1997;1:47–51.CrossRefPubMed
24.
Kauff ND, Perez-Segura P, Robson ME, et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high-risk Ashkenazi breast and ovarian cancer families. J Med Genet. 2002;39:611–4.CrossRefPubMedPubMedCentral
25.
Rennert G, Dishon S, Rennert HS, Fares F. Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel. Eur J Cancer Prev. 2005;14:357–61.CrossRefPubMed
26.
Zhang Y, Wu H, Yu Z, et al. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients. BMC Cancer. 2022;22:842.CrossRefPubMedPubMedCentral
27.
Kuschel B, Lux MP, Goecke TO, Beckmann MW. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Eur J Cancer Prev. 2000;9:139–50.CrossRefPubMed
28.
Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31:3091–9.CrossRefPubMedPubMedCentral
29.
Shubeck S, Sevilimedu V, Berger E, Robson M, Heerdt AS, Pilewskie ML. Comparison of outcomes between BRCA pathogenic variant carriers undergoing breast-conserving surgery versus mastectomy. Ann Surg Oncol. 2022;29:4706–13.CrossRefPubMed
30.
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: a nationwide cohort study. Breast. 2022;61:98–107.CrossRefPubMed
31.
Metadata
Title
Points to Consider Regarding De-Escalation Surgery in High-Risk Breast Cancer
Authors
Giovanni Corso, MD, PhD
Francesca Magnoni, MD, PhD
Paolo Veronesi, MD
Publication date
15-09-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12542-9

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

ASO Visual Abstract

ASO Visual Abstract: Very Early Recurrence After Curative-Intent Surgery for Gastric Adenocarcinoma

Gastrointestinal Oncology

Reply to: Letter to the Editor: Comment on “Prediction of Survival Outcomes Based on Preoperative Clinical Parameters in Gastric Cancer” by Bektaş, Mustafa et al.

Head and Neck Oncology

Clinical Practice Guidelines on Sentinel Lymph Node Biopsy for Melanoma: A Systematic Review and Quality Appraisal Using the AGREE II Instrument

ASO Visual Abstract

ASO Visual Abstract: Expanding Staging Criteria in T1–2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx

ASO Author Reflections

ASO Author Reflections: Management of the Lymph Node Basin in Cutaneous Melanoma—Patterns of Completion Dissection in a National Cohort

ASO Visual Abstract

ASO Visual Abstract: Contemporary Trends in Breast Reconstruction Use and Impact on Survival Amongst Women with Inflammatory Breast Cancer